Future research should focus on developing dual- or multi-target CAR-T therapies to address tumor heterogeneity, combining CAR-T therapy with immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) or radiotherapy to enhance efficacy, and utilizing gene-editing technologies (such as CRISPR) to develop universal CAR-T cells that reduce manufacturing costs. This evidence concerns the gene CD274 and neoplasm.